Puma Biotechnology Inc (PBYI NASDAQ) stock market data APIs
$3.6117
-0.02(-0.6%)
as of July 3, 2025
Try our APIs with
free plan!
Puma Biotechnology Inc Financial Data Overview
Price chart is built with
Anychart
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Prev. Close
3.6117
Open
3.5922
High
3.6429
Low
3.5542
52 wk Range
2.225-4.13
Market Cap
178 M
P/E Ratio
4.5897
Shares Outstanding
49 638 K
Revenue
233 M
EPS
0.1
Beta
1.279
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Puma Biotechnology Inc data using free add-ons & libraries
Get Puma Biotechnology Inc Fundamental Data
Puma Biotechnology Inc Fundamental data includes:
- Net Revenue: 233 M
- EBITDA: 48 672 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.22
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Puma Biotechnology Inc News
New
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, July 02, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2025, the Compensation Committee of Puma’s Board of Direc...
Insider Sale: Director at $PBYI Sells 10,800 Shares
TROY EDWARD WILSON, a director at $PBYI, sold 10,800 shares of the company on 06-13-2025 for an estimated $36,720. We received data on the trade from a recent SEC filing. This was a sale of approximat...
Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 6/5/2025
The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a ...
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
Have you been paying attention to shares of ANI Pharmaceuticals (ANIP)? Shares have been on the move with the stock up 8% over the past month. The stock hit a new 52-week high of $73.16 in the previou...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
